Dyslipidemias Clinical Trial
Official title:
Effect of Consumption of a Beverage of Chaya (Cnidoscolus Chayamansa) on Lipid Concentration, Lipid Peroxidation and Antioxidant Status of Patients With Dyslipidemia
NCT number | NCT04110392 |
Other study ID # | 2018-030 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2019 |
Est. completion date | December 7, 2020 |
Verified date | December 2023 |
Source | Hospital Regional de Alta Especialidad de la Península de Yucatán |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Currently, the changes generated in lifestyle, such as excessive consumption of saturated fats and refined carbohydrates, as well as the decrease in the intake of fiber, fruits, vegetables and antioxidants, as well as physical inactivity, have generated an increase in the prevalence of dyslipidemias. Dyslipidemias are a disorder of blood lipid and lipoprotein concentration, which increases the risk of developing atherosclerosis and cardiovascular diseases. In Mexico, the dyslipidemias are present in one in four Mexicans over 20 years old. However, in Yucatan increases this frequency increases due to one in three people suffer from dyslipidemia. Its prevalence is even higher in overweight subjects, diabetes and high blood pressure. Thus, it is important to search for strategies to reduce dyslipidemias, as well as the complications associated with them. The treatment and prevention of dyslipidemia is through dietary treatment, which may be accompanied by the consumption of foods that generate beneficial health effects due to the presence of bioactive compounds. Chaya (Cnidoscolus chayamansa) is a plant use in popular medicine to treat medicine in the treatment of chronic degenerative diseases. It contained different bioactive compounds such as flavonoids, vitamin C and polyphenols such as quercetin and kaempferol. Compounds that have been assigned various beneficial effects such as decreased triglyceride concentrations, cholesterol, malondialdehyde, C-Reactive protein, oxidized LDL, which are alterations that are present in dyslipidemia. Therefore, the consumption of this food could be an adequate strategy for subjects with dyslipidemia in Yucatan and Mexico due to the anti-inflammatory and antioxidant effects, and could reduce the risk of developing atherosclerosis and cardiovascular diseases.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 7, 2020 |
Est. primary completion date | September 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 60 Years |
Eligibility | Inclusion Criteria: - Male and female. - Adults between 20 and 60 years. - BMI = 20 and = 39.9 kg / m². - Mestizo Mexicans: parents and grandparents born in Mexico. - Patients diagnosed with dyslipidemia. - Dyslipidemia will be defined by any? alteration in the concentrations of the following lipoproteins: LDL cholesterol> 130mg/dL or total cholesterol> 200 mg/dL or triglycerides> 150 mg/dL - Patients should know how to read and write. - Signature of informed consent. Exclusion Criteria: - Patients with any type of diabetes previously diagnosed - Patients with acquired diseases that produce secondary obesity and diabetes. - Patients who have suffered a cardiovascular event. - Weight loss> 3 kg in the last 3 months. - Catabolic diseases such as cancer and acquired immunodeficiency syndrome. - Positive smoking. - Drug treatment: - Antihypertensive drugs (thiacyclic, loop or potassium-sparing diuretics, angiotensin II receptor blockers, alpha blockers, calcium antagonists, beta blockers). |
Country | Name | City | State |
---|---|---|---|
Mexico | Hospital Regional de Alta Especialidad de la Península de Yucatán | Mérida | Yucatán |
Lead Sponsor | Collaborator |
---|---|
Hospital Regional de Alta Especialidad de la Península de Yucatán |
Mexico,
Garcia-Rodriguez RV, Gutierrez-Rebolledo GA, Mendez-Bolaina E, Sanchez-Medina A, Maldonado-Saavedra O, Dominguez-Ortiz MA, Vazquez-Hernandez M, Munoz-Muniz OD, Cruz-Sanchez JS. Cnidoscolus chayamansa Mc Vaugh, an important antioxidant, anti-inflammatory and cardioprotective plant used in Mexico. J Ethnopharmacol. 2014 Feb 3;151(2):937-43. doi: 10.1016/j.jep.2013.12.004. Epub 2013 Dec 11. — View Citation
Kuti JO, Kuti HO. Proximate composition and mineral content of two edible species of Cnidoscolus (tree spinach). Plant Foods Hum Nutr. 1999;53(4):275-83. doi: 10.1023/a:1008081501857. — View Citation
Loarca-Pina G, Mendoza S, Ramos-Gomez M, Reynoso R. Antioxidant, antimutagenic, and antidiabetic activities of edible leaves from Cnidoscolus chayamansa Mc. Vaugh. J Food Sci. 2010 Mar;75(2):H68-72. doi: 10.1111/j.1750-3841.2009.01505.x. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline triglycerides concentration at 6 weeks of intervention | Serum triglyceride measurement by the method of colorimetry enzymatic | At the beginning of the study and after 6 weeks of intervention | |
Primary | Change from baseline Lipoproteins concentration at 6 weeks of intervention | Total cholesterol, LDL and HDL measurement by the method of colorimetry enzymatic | At the beginning of the study and after 6 weeks of intervention | |
Secondary | Change from baseline blood gene expression of superoxide dismutase at 6 weeks of intervention | Gene expression of superoxide dismutase measurement by qPCR method | At the beginning of the study and after 6 weeks of intervention | |
Secondary | Change from baseline blood gene expression of catalase at 6 weeks of intervention | Blood gene expression of catalase measurement by quantitative polymerase chain reaction (qPCR) method | At the beginning of the study and after 6 weeks of intervention | |
Secondary | Change from baseline serum antioxidant activity at 6 weeks of intervention | Serum antioxidant activity measurement by spectrophotometric method | At the beginning of the study and after 6 weeks of intervention | |
Secondary | Change from baseline serum C-Reactive Protein at 6 weeks of intervention | Serum C-Reactive Protein measurement by the method of colorimetry enzymatic | At the beginning of the study and after 6 weeks of intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Completed |
NCT04894318 -
The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients
|
N/A | |
Completed |
NCT04862962 -
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
|
||
Completed |
NCT04052594 -
A Study of LY3475766 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04270084 -
Metabolic Optimization Through Diet/Lifestyle Improvements For Youth
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04516291 -
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
|
Phase 2 | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Completed |
NCT04186780 -
Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study
|
N/A | |
Not yet recruiting |
NCT03674333 -
Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Terminated |
NCT01697735 -
The Therapeutic Effects of Statins and Berberine on the Hyperlipemia
|
Phase 4 | |
Completed |
NCT00362908 -
Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome
|
N/A | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Completed |
NCT00644709 -
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
|
Phase 4 | |
Recruiting |
NCT05624658 -
Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS
|
N/A | |
Recruiting |
NCT03988101 -
Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event
|
Phase 4 | |
Recruiting |
NCT06024291 -
Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial
|
N/A | |
Completed |
NCT01218204 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
|
Phase 2 |